Several criteria were imposed to select an optimal founder population; these included similar SIY expression based on DsRed intensity, comparable tumor growth kinetics to polyclonal B16.SIY tumors in vivo, and normal efficacy response to anti-PD-L1 blockade in vivo (Supplementary Fig. 2a and b). Here, CD274 is linked to neoplasm.